ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0081 • ACR Convergence 2020

    Prevalence of Systemic Autoimmune Diseases in Polycystic Ovary Syndrome

    Saika Sharmeen1, Hafsa Nomani2, Erin Taub3 and Qingping Yao3, 1Stony Brook University Renaissance School of Medicine, Dix Hills, NY, 2Stony Brook University Renaissance School of Medicine, West Babylon, NY, 3Stony Brook University Renaissance School of Medicine, Stony Brook, NY

    Background/Purpose: Polycystic ovary syndrome (PCOS) is characterized by hormonal abnormality, chronic anovulation, hyperandrogenism, and obesity. Due to the hormonal imbalance, we hypothesize that patients with…
  • Abstract Number: 0146 • ACR Convergence 2020

    Patients’ Perceptions and Expectations Towards the Role of Rheumatologists in the Recommendations of Physical Activity’s Practice – A Cross-sectional Study Involving 308 Patients Living with Rheumatoid Arthritis in France

    Anne-Christine Rat1, Arnaud Constantin2, Catherine Beauvais3, Yannick Guillodo4, Valérie Guay5, Emilie Pain6, Alexis Bombezin--Domino6 and Florence E Lévy Weil7, 1Universite de Caen Normandie and Université de Lorraine, EA 4360, Caen, France, 2Hospital Pierre Paul Riquet, Toulouse, France, 3Saint-Antoine Hospital, AP-HP, Rheumatology Department, Sorbonne-Université, Paris, France, Paris, France, 4La Cavale Blanche University Hospital, Rheumatology Department, Brest, France, Brest, France, 5Argenteuil Hospital, Physiotherapist, Health executive, Argenteuil, France, Argenteuil, France, 6Carenity, Online Patient Community, Paris, France, Paris, France, 7Sanofi Genzyme, Gentilly, France, Gentilly, France

    Background/Purpose: Rheumatologists consider physical activity (PA) to be an important goal in the care for patients with rheumatoid arthritis (RA). However, there are very few…
  • Abstract Number: 0183 • ACR Convergence 2020

    Incidence of Malignancies in Japanese Patients with Rheumatoid Arthritis: Data from a Large Japanese National Registry

    Toshihiro Matsui1, Naonobu Sugiyama2, Tsutomu Kawaguchi2, Aosa Kamezaki2, Shigeyuki Toyoizumi3, Fujio Matsuyama4, Tatsunori Murata4, Yukitomo Urata5, Kimito Kawahata6 and Shigeto Tohma7, 1Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan, 2Pfizer Japan Inc, Tokyo, Japan, 3Pfizer R&D Japan G.K., Tokyo, Japan, 4CRECON Medical Assessment Inc, Tokyo, Japan, 5Department of Rheumatology, Tsugaru General Hospital, Aomori, Japan, 6Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 7National Hospital Organization Tokyo National Hospital, Tokyo, Japan

    Background/Purpose: Patients (pts) with RA have an increased risk of some malignancies compared with the general population, and this can vary by region/race.1,2 Epidemiologic data…
  • Abstract Number: 0199 • ACR Convergence 2020

    A Phase 1, Randomized, Open-label, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17, a Proposed, Higher Concentration Biosimilar (100 mg/mL) Adalimumab, in Healthy Subjects

    Edward C Keystone1, Daniel Furst*2, Jonathan Kay3, EunJin Choi4, Antonia Davidson5, YunJu Bae4, Darin Brimhall6, SangJoon Lee4, SungHyun Kim4 and DaHye Kwak4, 1Mount Sinai Hospital, Toronto, ON, Canada, 2Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, 3University of Massachusetts Medical School, Worcester, MA, 4Celltrion, Inc., Incheon, Republic of Korea, 5PPD Development, Austin, TX, 6PPD Development, Las Vegas, NV

    Background/Purpose: CT-P17 is a recombinant human monoclonal antibody that was developed as the first biosimilar adalimumab with high concentration (100 mg/mL) and citrate-free formulation. The…
  • Abstract Number: 0215 • ACR Convergence 2020

    Incidence and Risk of Venous Thromboembolic Events Among Patients with Rheumatoid Arthritis Enrolled in the Upadacitinib Clinical Trial Program

    Ernest Choy1, Iain McInnes2, John Cush3, Jacob Aelion4, William Rigby5, Yanna Song6, Sebastian Meerwein7, John Liu8, Nasser Khan8, Jessica Suboticki8 and Alexander Cohen9, 1CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 2Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 3University of Texas Southwestern Medical School, Dallas, TX, 4Arthritis Clinic PLLC, Jackson, 5Dartmouth College, Norwichi, VT, 6AbbVie Inc., North Chicago,, IL, 7Pharmaceutical Development, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, 8AbbVie Inc., North Chicago, IL, 9Guy’s and St Thomas’ NHS FT Hospitals, King’s College, London, United Kingdom

    Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) are at an increased risk for the development of venous thromboembolism (VTE, including pulmonary embolism [PE] and deep…
  • Abstract Number: 0232 • ACR Convergence 2020

    Safety and Effectiveness of Tocilizumab in Patients with Renal Insufficiency in the Non-interventional Study ICHIBAN

    Christof Specker1, Martin Aringer2, Gerd Burmester3, Johannes Gerlach4, Michael Hofmann5, Herbert Kellner6, Frank Moosig7, Hans-Peter Tony8 and Gerhard Fliedner9, 1Clinic Essen-Mitte, Essen, Germany, 2Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany, 3Charité University Hospital Berlin, Berlin, Germany, 4Roche Pharma AG, Grenzach-Wyhlen, Germany, 5Chugai, Frankfurt am Main, Germany, 6Rheumatology and Gastroenterology Specialty Practice, Munich, Germany, 7Rheumatology Center Schleswig-Holstein Middle, Neumünster, Germany, 8Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, 9Rheumatology Practice, Onsabrück, Germany

    Background/Purpose: RA increases a patient’s systemic inflammatory burden, which has been associated with development of chronic kidney disease (CKD), especially in patients with comorbid hypertension,…
  • Abstract Number: 0452 • ACR Convergence 2020

    Recombinant Zoster Vaccine in Patients with Rheumatic Diseases: A Retrospective Study of 622 Patients

    Tiphaine Lenfant1, Elizabeth Kirchner2, Rula Hajj-ali3, Leonard Calabrese3 and Cassandra Calabrese3, 1Cleveland Clinic Foundation, Rocky River, OH, 2Cleveland Clinic Foundation, Cleveland, 3Cleveland Clinic, Cleveland, OH

    Background/Purpose: The recombinant herpes zoster vaccine (RZV) was FDA-approved in 2017 but patients with rheumatic diseases were excluded from initial pivotal trials because of theoretical…
  • Abstract Number: 0493 • ACR Convergence 2020

    Automatic Joint Space Assessment in Hand Radiographs with Deep Learning Among Patients with Rheumatoid Arthritis

    Yun-Ju Huang1, Chang-Fu Kuo1, Fakai Wang2, Shun Miao2, Kang Zheng2 and Le Lu2, 1Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China), 2PAII labs, Bethesda, MD

    Background/Purpose: Assessment of joint space is the fundamental radiographic task to diagnose rheumatoid arthritis (RA) and to assess the severity and progression of the disease.…
  • Abstract Number: 0740 • ACR Convergence 2020

    Card9 Promotes Th17-mediated Arthritis and Spondylitis via Control of Acute Pathogenic Neutrophil Responses in SKG Mice

    Holly Rosenzweig1, Emily Vance1, Ellen Lee1 and Ruth Napier1, 1Oregon Health & Science University and VA Portland Health Care System, Portland, OR

    Background/Purpose: Caspase recruitment domain-containing protein 9 (CARD9) is an intracellular signal transduction molecule that mediates antimicrobial responses following activation of C-type lectin receptors (ie. Dectin-1) by…
  • Abstract Number: 0757 • ACR Convergence 2020

    Sunlight Exposure, Sun-protective Behaviour, and Anti-citrullinated Protein Antibody Positivity: A General Population-based Study in Quebec, Canada

    Naizhuo Zhao1, Audrey Smargiassi2, Ines Colmegna3, Marie Hudson4, Marvin Fritzler5 and Sasha Bernatsky6, 1McGill University, Montreal, Canada, 2l’Université de Montréal, Montreal, Canada, 3The Research Institute of the McGill University Health Centre, Montreal, Canada, 4Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, 5Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 6The Research Institute of the McGill University Health Centre, Montreal, ON, Canada

    Background/Purpose: Sunlight exposure has been associated with lower rheumatoid arthritis (RA) risk, but to our knowledge, no one has ever studied sunlight exposure and anti-citrullinated…
  • Abstract Number: 0775 • ACR Convergence 2020

    T and B Cell Responses to Common Tenascin-C Peptides in RA

    JING Song1, Anja Schwenzer2, Sara Turcinov3, Alicia Wong2, Cliff Rims1, Lorena Rodriguez Martinez2, David Arribas-Layton4, Christina Gerstner5, Virginia Muir6, Jeffrey Carlin7, Kim Midwood2, Vivianne Malmström8, Eddie James1 and Jane Buckner1, 1Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, 2Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 3Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Institutet, Stockholm, Sweden, 4Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, 5Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, 6Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, 7Department of Rheumatology, Virginia Mason Medical Center, Seattle, WA, 8Karolinska Institutet, Stockholm, Stockholms Lan, Sweden

    Background/Purpose: Although autoreactive CD4+ T cell and antibody responses against citrullinated antigens are known to contribute to loss of immune tolerance in rheumatoid arthritis (RA),…
  • Abstract Number: 0792 • ACR Convergence 2020

    LY294002 Improves the Collagen-induced Arthritis by Inducing Neutrophil Apoptosis

    Xuechan Huang1, Tianwang Li1, Shuyang Chen1, Zhixiang Huang1 and Junming Chen1, 1Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangdong, China (People's Republic)

    Background/Purpose: Neutrophils play a central role in host defense, but they also play important effectors on acute and chronic inflammation. Neutrophil apoptosis is essential for…
  • Abstract Number: 0808 • ACR Convergence 2020

    Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort

    Mohammad Movahedi1, Angela Cesta2, Xiuying Li3, Edward C Keystone4 and Claire Bombardier5, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2Toronto General Hospital Research Institute, Toronto, ON, Canada, 3Toronto General Hospital Research Institute, Toronto, Canada, 4Mount Sinai Hospital, Toronto, ON, Canada, 5Institute for Work and Health, Toronto, ON, Canada

    Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). TOFA can…
  • Abstract Number: 0825 • ACR Convergence 2020

    Sex Differences in the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis Patients: A Post Hoc Analysis of Phase 3 and Long-Term Extension Trials

    Niall Jones1, Vibeke Strand2, Hendrik Schulze-Koops3, Eduardo Mysler4, Cassandra D Kinch5, David Gruben6, Rebecca Germino7, Carol A Connell6 and Lihi Eder8, 1Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, 2Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 3Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, 4Organización Médica de Investigación, Buenos Aires, Argentina, 5Pfizer Canada ULC, Kirkland, QC, Canada, 6Pfizer Inc, Groton, CT, 7Pfizer Inc, New York, NY, 8Women’s College Research Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Differences in efficacy outcomes favoring male vs female patients (pts) with RA have been reported with csDMARDs1 and TNF inhibitors;2 results with JAK inhibitors…
  • Abstract Number: 0968 • ACR Convergence 2020

    Combined Inhibition of Autophagy and Glutamine Metabolism Suppresses Cell Growth of RA Synoviocytes and Ameliorates Arthritis in SKG Mice

    Ikuko Naka1, Jun Saegusa2, Kenichi Uto2, Yuzuru Yamamoto3, Yoshihide Ichise4, Hirotaka Yamada4, Yo Ueda5, Takaichi Okano4, Soshi Takahashi6, Sho Sendo7 and Akio Morinobu8, 1Kobe University, Kobe, 2Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan, 3Kobe University, Kobe-city, Japan, 4Kobe University, Kobe, Japan, 5Kobe UniversityRheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, 6Kobe univerity, Kobe, Japan, 7Kobe university, Kobe city, Japan, 8Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan

    Background/Purpose: Immunometabolism is now recognaized to be crucial in the pathogenesis of rheumatoid arthritis (RA). We have recently shown that the expression of glutaminase 1…
  • « Previous Page
  • 1
  • …
  • 132
  • 133
  • 134
  • 135
  • 136
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology